INVITATION TO A TELECONFERENCE AND PRESENTATION OF AEROCRINE’S INTERIM REPORT ON NOVEMBER 27

SOLNA, Sweden - Aerocrine AB (NASDAQ Stockholm: AERO) will publish its report for the third quarter and first nine months of 2014 on November 27 at 08:00 am CET.

A teleconference will be held for analysts, the media and investors on the same day at 09:15 am (CET). The report will be presented by Scott Myers, CEO and Marshall Woodworth, CFO.

The presentation will be held in English. After the presentation there will be an Q&A session via the teleconference.

For participation via the teleconference please call in five minutes prior to the specified time to ensure a punctual start to the meeting. Call in at: +46 8 519 99 356 (Sweden) +44 20 319 40 554 (UK) +1 8 552 692 607 (US)

The presentation will also be available ondemand at www.aerocrine.com

For more information about Aerocrine:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219

Or visit www.aerocrine.com

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.

About Us

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Subscribe

Documents & Links